Shivom (OMX) Blockchain DNA Data Hub and eMQT Partner for Sickle Cell Disease Treatments
Shivom Partners with eMQT, Helping to Give African Communities Access to Healthcare Through Blockchain Technology
Most people know that Shivom is a decentralized platform that hosts the largest data hub for genomics in the world. In their recent token sale, they managed to reach their goal of a $35 million market cap in just 15 seconds. However, it is time for them to make some progress in their goal of establishing global healthcare access, and they are partnering with eMQT to do it.
eMQT is a non-profit organization, which will help them bring research experts and technology to the underserved areas in Africa. It is their hope that this partnership will help them bring forward their digital healthcare on the blockchain in the area. Both companies have a mutual plan to collect the genomic data of 1000 patients that suffer with Sickle Cell Disease, which is common in the county. Their work will help them create an opportunity for clinical trials and other medical efforts to take place for the population.
Shivom’s blockchain is necessary for this process, allowing the collaboration to store the patient information safely and security. The data collected will be based on eMQT’s platform, which will assist with sharing the data to the appropriate entities. There will be a specific group of SCD patients used for their technology, specifically from Sub-Sahara African and the United Kingdom.
The companies have planned to start with collecting 100 genomic data samples. However, they plan to raise that number to 1000, which will all be stored within the Shivom platform. To perform the collection, eMQT will use their resources to connect with institutions that will give them patient access to SCD sufferers.
The goal is to bring this information to the rest of the medical community, urging them to be aggressive in finding treatment solutions. It will also help the medical community to gain a greater understanding of the disease, and how various genomic factors play a role. Not only will this help doctors and scientists to find the right treatment plan, but it will help them to improve upon those plans and create new ones. Furthermore, patients that need treatment for SCD will have access to doctors that can give them more information and help them to prepare to treat their condition with a solution that is catered to them.
Right now, in Sub-Saharan Africa, nearly 3% of all births involve a child that will be diagnosed with SCD, which is substantial, considering that the women in this area have the highest fertility rate in the world. In the United Kingdom, there were 14,000 people reported to have SCD in 2016 alone. With the use of blockchain to store patient data, it will be easier for these sufferers to keep their medical information updated for their current doctor, which means that treatment comes easier. However, the secured blockchain will be reserved for use by physicians that need to access details about their patients, and patients have controlled options when it comes to sharing this information.
Dr. Natalie Pankova, who is presently the chief operating officer for Shivom, said, “We’re proud to work with an organisation such as eMQT, and we believe in the pursuit of this project. We have the ability to make a real impactful change to precision medicine and global healthcare as a whole. Using our innovative technology, we will collect and store genomic data that will be properly assessed and researched by authorized professionals, to streamline treatment and disease management to an underserved population.
eMQT seems to be in this partnership with the intention of urging the entities in charge to initiate more clinical trials in these types of populations. However, to help this process along, they also have their own services available that emphasize the importance of a diverse representation of these populations. These trials collect important genomic data that could reshape the pharmaceutical industry and the quality of treatment.
In a statement from Adama Ibrahim, the founder and chairperson of eMQT, this objective is further explained:
“eMQT is excited to facilitate such a meaningful project alongside Shivom that aligns with our long-term vision for the future of technology combined with clinical research. As we move forward, our sights are set on helping a population that is currently underrepresented and experiencing a gap between their disease and proper medical care, which requires a thorough understanding of their needs through generating sustainable access to high-quality data for research and testing.”